Abstract: A biogas treatment process is integrated with a water treatment process to adjust the pH level of the water and to provide more effective disinfection of the water. A water wash process is utilized to separate methane and carbon dioxide present in the biogas. During the water wash process, the biogas is mixed with water and the carbon dioxide is absorbed into the water. Because the process typically occurs at an elevated pressure and reduced temperature to enhance the solubility of carbon dioxide in water, the water stream becomes supersaturated with carbon dioxide. This water stream, which is supersaturated with carbon dioxide, is provided to the water treatment process to adjust the pH level of the water treatment process. The pH level is regulated to a desired level such that an increased relative concentration of hypochlorous acid is produced when sodium hypochlorite is added to the treatment process.

Abstract: Disclosed herein are Fenton filters comprising a porous substrate and a catalyst coating the porous substrate, wherein the catalyst includes a matrix and single metal atoms incorporated in the matrix. Also disclosed herein are methods of generating radicals from an oxidant, electrolyzers, methods of generating hydrogen peroxide, and water treatment systems.

Abstract: The invention proposes a process of in-line mineralisation of water according to which demineralised water is circulated in a pipe inside which enzymes are immobilised to catalyse the reaction of carbon dioxide and water to form bicarbonate, carbon dioxide is introduced into the pipe, and a pre-determined quantity of solid minerals, preferably magnesium and/or calcium carbonate, is introduced into the circulating water. The process enables to accelerate the dissolution of carbon dioxide in the water, which optimises the dissolution of minerals for in-line mineralisation of water, i.e., without stopping the circulation of water. The invention also proposes a system for implementing the process.

Abstract: A method of increasing operational efficiency of a power plant includes determining an average rate of accumulation of scale-forming compounds in a cooling water source, directing water from the cooling water source having a first concentration of scale forming compounds through a treatment system to produce a treated water having a lower concentration of scale-forming components than the first concentration by operating the treatment system with operating parameters selected such that a rate of removal of the scale-forming components from the water in the treatment system is greater than the average rate of accumulation of the scale-forming components, directing the treated water back into the cooling water source, and circulating water including the treated water from the cooling water source through a cooling system of the power plant.

Abstract: An integrated equipment and treatment method for synchronous ecological treatment of domestic sewage and sludge, the equipment includes a one-piece box-shaped main body divided into several tank compartments which includes an anaerobic tank, a sludge reduction and denitrification tank, an aerobic tank, a sedimentation tank, and a disinfection tank, an inlet pipe for sewage and sludge entrance and an outlet pipe for exit of effluent after treatment. The sludge reduction and denitrification tank is equipped with variable microporous aeration pipes, worm fillers and multi-functional water quality online detectors. The aerobic tank is equipped with aeration pipeline components and DO online detectors. The sewage and sludge are guided to passing through the different tank compartments in order for simultaneous sewage treatment and sludge reduction. The removal rate of total nitrogen is as high as 85%, and the simultaneous reduction effect of sludge can reach more than 60%.

Abstract: Provided is a glass fine particle deposit in which a pH of glass fine particles on a surface of the glass fine particle deposit is 5.5 or more and less than 8.5, in which a color difference ?E*ab with respect to a white calibration plate when the surface of the glass fine particle deposit is measured by the SCI method using a spectrophotometer is 0.5 or more and less than 5. Provided is a method for manufacturing a glass preform including: manufacturing a transparent glass preform by heating a glass fine particle deposit in which a pH of glass fine particles on a surface of the glass fine particle deposit is 5.5 or more and less than 8.5; and measuring the surface of the deposit by the SCI method using a spectrophotometer and determining whether a color difference ?E*ab with respect to a white calibration plate is 5 or more.

Abstract: A system for melting materials during the production of a glass or ceramic material is disclosed. A method for melting materials during the production of a glass or ceramic material is also disclosed. The system comprises a melt tank having an interior with a width and a length; and an electrode array comprising a plurality of elongate electrodes each extending at least partially across the width of the interior of the melt tank. Each electrode within the electrode array is spaced apart from an adjacent electrode within the electrode array by from about 5 mm to 100 mm. The electrode array is configured such that during a heating operation, current flows between adjacent electrodes within the electrode array, such that heat is radiated from the electrodes to materials located within the interior of the melt tank.

Abstract: The present invention relates to a roto-linear mechanism for a glassware forming machine adapted to be connected to a funnel-holding arm, a shutter arm, an arm for a blowing head or a similar mechanism, to simultaneously perform an axial and radial movement to each of such arms from a first position to form glass articles to a second position outside the forming process thereof.

Abstract: The invention relates to a fibrous mat facer for preparing a gypsum board, to a gypsum board comprising said mat facer and to a system comprising said gypsum board. The fibrous mat comprises at least one ply of a non-woven fabric, and a binder composition, wherein the binder composition represents from 10 to 40 wt % of the total weight of the mat. The binder composition comprises a copolymer comprising a co-monomer unit of a vinyl ester of an alpha branched aliphatic monocarboxylic acid, said copolymer being present in an amount from 25 to 100 wt % of the binder composition weight.

Abstract: A method for increasing the tactile feel of a glass-ceramic article includes (a) performing a first etching of a surface of the glass-ceramic article with a first etchant to create a plurality of features on the surface, wherein the first etchant comprises hydrofluoric acid and an inorganic fluoride salt, and the plurality of features comprises protrusions and recesses and (b) performing a second etching of the surface with a second etchant different from the first etchant to enlarge a distance between adjacent features of a same type, wherein the second etching occurs after the first etching, after the second etching an average distance between adjacent features of a same type is in a range from 0.5 ?m to 20 ?m and a density of features of the same type is in a range from 9,000 to 25,000 features/mm2, and a tactile feel of the surface after the second etching is greater than the tactile feel of the surface before the first etching.

Abstract: Embodiments of a deadfront article are provided. The deadfront article includes a substrate having a first surface and a second surface. The deadfront article also includes a semi-transparent layer disposed onto the second surface of the substrate. The semi-transparent layer has a region of a solid color or of a design of two or more colors, and the semi-transparent layer has a first optical density. Further, the deadfront article includes a contrast layer disposed onto the region. The contrast layer is configured to enhance visibility of the color(s) of the semi-transparent layer.

Abstract: Provided herein are glass substrate multilayer structure, a manufacturing method thereof, and a flexible display panel including the same. Also provided is a glass substrate multilayer structure that has remarkably good surface hardness, has remarkably good impact resistance, can provide for safety of a user by resisting scattering when the glass substrate is broken, and has excellent optical properties. The disclosure also relates to a manufacturing method the glass substrate multilayer structure, and a flexible display panel including the same.

Abstract: Asymmetrically strengthened glass articles, methods for producing the same, and use of the articles in portable electronic device is disclosed. The asymmetrically strengthened glass articles include glass articles having a deeper compressive stress layer in a thicker portion of the glass article. Using a budgeted amount of compressive stress and tensile stress, asymmetric chemical strengthening is optimized for the utility of a glass article. In some aspects, the strengthened glass article can be designed for reduced damage, or damage propagation, when dropped.

Abstract: A method of performing ion exchange of a thin, flexible glass substrate having an average thickness equal to or less than about 0.3 mm to chemically strengthen the glass substrate is disclosed. The chemically strengthened glass substrate comprises a first compressive stress layer having a first depth of layer, and a second compressive stress layer having a second depth of layer, the first and second stress layers being separated by a layer of tensile stress. A laminated article comprising the chemically strengthened glass substrate is also described.

Abstract: Provided herein is a method of and system for processing an optical fiber. The method includes the steps of drawing an optical fiber in a drawing direction along a process pathway through a coating chamber comprising an inlet and an outlet, and a coating liquid volume to coat the optical fiber; supplying the coating liquid through the inlet, the coating liquid exiting the coating chamber through the outlet; and recirculating to coating liquid exiting the coating chamber to the inlet.

Abstract: A glass of the present invention includes as a glass composition, in terms of mass %, 55% to 70% of SiO2, 15% to 25% of Al2O3, 1% to 5% of B2O3, 0% to 0.5% of Li2O+Na2O+K2O, 0% to 4% of MgO, 3% to 11% of CaO, 0% to 4% of SrO, and 0% to 11% of BaO, and has a strain point of more than 715° C.

Abstract: Athermal glasses and athermal systems for infrared optical components and systems are disclosed.

Abstract: A geopolymer cement and a method of producing the same are provided. A geopolymer cement binder may be provided including a geopolymer precursor and magnesium oxide as an alkali activator. The geopolymer cement binder may be mixed with water using high shear mixing.

Abstract: Carbonatable calcium silicate-based cements and concretes are presented, which result in concrete compositions that have an improved aesthetics. A cement product includes a plurality of particles of a carbonatable calcium silicate cement and a first additive; wherein, the first additive is a hydrophobic organic acid, or a salt thereof, or a silane, or a polysiloxane.

Abstract: The present invention relates to an enhanced ceramic coating composition comprising a base non-stick ceramic coating composition and 0.2 wt %-2 wt % diamond additive (DA) with wt % compared with the total weight compared of the ceramic coating composition, wherein the diamond additive comprises diamond and mica particles, and wherein said mica particles comprise coloured mica particles, such as red and/or green and/or blue coloured mica particles. It also relates to a method of coating an artefact with the improved ceramic coating, and an artefact provided with a dry film coating containing an improved ceramic coating prepared using an improved ceramic coating composition of the invention. An artefact coated with the improved ceramic coating has the combined advantages of durable non-stick, scratch resistance and abrasion resistance.

Abstract: A long-term ablation-resistant nitrogen-containing carbide ultra-high temperature ceramic with an ultra-high melting point is prepared as follows: preparing the HfC powder and the HfN powder according to a mass ratio of HfC:HfN=(1-7):1; uniformly mixing the HfC powder and the HfN powder with the carbon powder and the carbon nitride powder to obtain a mixed powder, wherein the amount of the carbon powder and the amount of the carbon nitride powder do not exceed 8.0 wt. % and 5.0 wt. %, respectively, of the mixed powder mass; and performing spark plasma sintering on the mixed powder to produce the ceramic with the ultra-high melting point, a density ?98%, and a uniform C/N content distribution. The ultra-high temperature ceramic is suitable for ultra-high temperature ablation-resistant protection at ?3000° C. The ceramic maintains a close to zero ablation rate and a continuously stable oxidation-resistant protective structure after ablation for 300 s.

Abstract: The invention provides methods and compositions that prevent, mitigate or delay the onset of corrosion of iron or steel (e.g., plain carbon steel) components used as reinforcement or otherwise at least partially embedded in carbonated concrete composite materials and objects based on carbonatable calcium silicate cement.

Abstract: The disclosure relates to an agricultural composition comprising paraformaldehyde, a nitrification inhibitor, urea, an ammonia source, or a combination thereof and one or more reaction products prepared from paraformaldehyde, a nitrification inhibitor, urea, an ammonia source, and optionally a solvent, wherein the one or more reaction products is present in an amount of at least 20 wt. % of the total weight of the agricultural composition. Also discloses is a fertilizer composition comprising the agricultural composition and a nitrogen source. Further disclosed are processes for preparing an agricultural composition.

Abstract: The invention relates to a method for converting a gas into methane (CH4) which includes: a step of activating a catalytic material including praseodymium oxide (Pr6O11) associated with nickel oxide (NiO) and alumina (Al2O3), the respective proportions of which are, relative to the total mass of these three compounds: Pr6O11: 1 wt % to 20 wt %, NiO: 1 wt % to 20 wt %, and Al2O3: 60 to 98 wt %; and a step of passing a gas including at least one carbon monoxide (CO) over the activated catalytic material.

Abstract: An object is to provide a cage silicate that can be industrially safely and simply produced by using an alkali silicate solution that does not generate alcohol as a Si raw material and using non-toxic quaternary ammonium, and a method for producing the same. The problem is solved by the following cage silicate: A cage silicate consisting of anion component 1 represented by following formula (1), anion component 2 which is a mineral acid ion, cation component 1 represented by following formula (2), and cation component 2 which is an alkali ion, in which, to the mole number in terms of SiO2, a ratio of the mole number of water, (H2O/SiO2), is 0.7 to 30, a ratio of the mole number of alkali ions, (alkali ions/SiO2), is 1.0×10?7 to 1.0?10?2, and a ratio of the mole number of the mineral acid ions, (mineral acid ions/SiO2), is 1.0×10?7 to 1.0×10?3. In formula (2), R represents an alkyl group having 2 to 20 carbon atoms.

Abstract: Compositions containing at least one compound of formula I where R1 is a phenolic compound (e.g., simple phenol, creosote, thymol, or carvacrol), and where R2 is a polyamine (e.g., ethylenediamine (EDA), diethylenetriamine (DETA), triethylenetetramine (TETA), tetraethylenepentamine (TEPA), hexamethylenediamine (HDA)); and optionally a carrier; the compositions may additionally contain at least one epoxy resin. Methods for killing microorganisms involving contacting the microorganisms with an effective microorganism killing amount of the above composition. Compositions containing at least one compound produced by a method involving reacting phenolic-branched chain fatty acid methyl ester with at least one polyamine.

Abstract: In one aspect, compounds modulating sirtuin activity are described herein. Sirtuin modulation by compounds described herein includes sirtuin activation and sirtuin inhibition. Modulation of sirtuin activity includes sirtuin activation and/or sirtuin inhibition. In some embodiments, a sirtuin modulating compound and/or salt thereof is of Formula I described herein.

Abstract: A process can produce alcohols having at least two carbon atoms by catalytic conversion of synthesis gas into a mixture containing alkanes, alkenes, and alcohols. Alkenes are converted into corresponding alcohols in a subsequent step by hydration of the alkanes. Before the hydration and after the catalytic conversion, gas and liquid phases may be separated. Specific catalysts can be employed that have a markedly higher selectivity for alkenes than for alkanes. These catalysts comprise grains of non-graphitic carbon having cobalt nanoparticles dispersed therein. The cobalt nanoparticles have an average diameter dp from 1 to 20 nm, and an average distance D between nanoparticles is from 2 to 150 nm. The combined total mass fraction of metal ? in the grains ranges from 30% to 70% by weight of the total mass of the grains of non-graphitic carbon, wherein 4.5 dp/?>D?0.25 dp/?.

Abstract: A process for synthesis of urea from ammonia and carbon dioxide wherein: the urea synthesis is performed with a stripping process in a synthesis loop including at least a reactor (1), a stripper (2) and a condenser (3); the reactor effluent is treated in the stripper to remove unreacted ammonia and carbon dioxide; the urea solution (14) from the stripper is sent to a low-pressure recovery section (4); the stripper vapours are split into a first portion (151) directed to the reactor and a second portion (152) sent to the condenser; the condenser (3) is a shell-and-tube kettle condenser where condensation of stripper vapours is performed in the tube side (30); a carbamate-containing effluent (20) from the condenser is returned to the reactor.

Abstract: This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPAR? or a ?-opioid receptor.

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The invention relates to clinical chemistry, in particular, to new biologically active compounds—amide derivatives of prostaglandin F2?. These compounds have low cytotoxicity and are capable of stimulating formation of endogenous nitrogen oxide in mammal cells. Synthesis of such compounds promotes expansion of nomenclature of biologically active derivatives of prostaglandin F2? capable of reducing intraocular pressure.

Abstract: Systems and methods of producing olefins via catalytic cracking are disclosed. Hydrocarbons of a naphtha stream are isomerized by converting straight chain Cn hydrocarbons to branched Cn hydrocarbons, thereby forming an isomerized naphtha stream. The isomerized naphtha stream is subsequently fed to a catalytic cracking unit such that the hydrocarbons of the isomerized naphtha stream form olefins. In the catalytic cracking process, the reaction temperature can be kept lower than 680° C., thereby increasing the reactivity and minimizing catalyst deactivation in the catalytic cracking process.

Abstract: The invention relates to a method for producing one or more olefins and one or more carboxylic acids, in which one or more paraffins is or are subjected to an oxidative dehydrogenation. For the oxidative dehydrogenation, a reactor (10) having a plurality of reaction zones (11, 12, 13) is used, a gas mixture comprising the one or more paraffins is successively passed through the reaction zones (11, 12, 13), and at least two of the reaction zones (11, 12, 13) are subject to varying temperature influences. The invention also relates to a corresponding system (100).

Abstract: The present invention relates to a process for preparing the 2-bromoglutaric acid diester of formula (I) below: comprising the formation of the 2-hydroxyglutaric acid diester of formula (II) by reaction of butyrolactone acid of formula (BA) with the alcohol of formula ROH, in the presence of an acid such as sulfuric acid; and bromination of the 2-hydroxyglutaric acid diester of formula (II), by sparging with gaseous hydrobromic acid. The present invention also relates to a 2-bromoglutaric acid diester of formula (I), having a degree of purity determined by HPLC analysis of greater than or equal to 90%.

Abstract: Provided are a method of purifying an alpha-olefin and a composition for purifying an alpha-olefin therefor. More specifically, a method of purifying an alpha-olefin having an excellent effect of removing impurities in the alpha-olefin and a composition for purifying an alpha-olefin therefor are provided.

Abstract: Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of making and using the same.

Abstract: Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to novel anisotropic compounds of formula as well as to liquid crystalline mixtures, films and electro-optical devices comprising the compound.

Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.

Abstract: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.

Abstract: A 4,5-bis(4-methoxyphenyl)-1-hexyl-2-phenyl-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The invention relates to new olaparib oxalic acid cocrystals. The olaparib oxalic acid cocrystals vary in ratio from 1:1 to 2:3 olaparib:oxalic acid. In particular, the invention relates to a 2:3 olaparib oxalic acid cocrystal, a 1:1 olaparib oxalic acid cocrystal, and a 2:1 olaparib oxalic acid cocrystal. The invention also relates to pharmaceutical compositions containing an olaparib oxalic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib oxalic acid cocrystals of the invention Got may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP). These include cancer, fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms of critical illness (e.g. septic shock, ALI, acute liver failure).

Abstract: The present invention relates to a triazine compound and a use thereof. Specifically, the amphipathic triazine compound according to the present invention has a strong anti-bacterial effect and anti-inflammatory effect, while being excellently effective for preventing, alleviating, or treating an allergy. Also, the triazine compound according to the present invention is expected to be usefully utilized as a compound for external application on the skin, which is not toxic and can be safely used on the skin.

Abstract: A 4-chloro-N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A compound represented by the following formula (1): The R1 to R9, L1 to L3, and Ar1 to Ar2 in the formula (1) are as defined in the description. An organic electroluminescence device contains the compound, and an electronic instrument includes the organic electroluminescence device.

Abstract: The present invention provides flavone derivatives having the general formula (I) which are useful for the treatment of Hepatitis B Virus infection (HBV). The compounds act as cccDNA (covalently closed circular DMA) inhibitors.

Abstract: A 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.